SAN CARLOS, Calif.-- October 14, 2026 -- Altay Therapeutics, Inc., a biotechnology company developing novel small molecule inhibitors of transcription factors, today announced the completion of a $37 million Series...


Balance Therapeutics is a clinical-stage pharmaceutical company developing therapies to improve the lives of patients with debilitating neurological conditions. The company focuses on areas of high unmet medical need where neurobiological pathways provide a strong rationale for our pharmacological approach. Balance's experienced drug development team is committed to advancing products to deliver life-improving medicines that serve patients and their families. The company's principal areas of focus are sleep disorders and cognitive deficits.